Department of Radiology, Hospital Clínic de Barcelona, Barcelona, Spain.
Department of Radiology, Hospital Clínic de Barcelona, Barcelona, Spain.
Eur J Radiol. 2021 Mar;136:109509. doi: 10.1016/j.ejrad.2020.109509. Epub 2021 Jan 14.
To evaluate the non-inferiority of oral hydration compared to intravenous (i.v.) hydration in the prevention of post-contrast acute kidney injury (PC-AKI) in patients with stage IIIb chronic kidney disease (CKD) referred for an elective contrast-enhanced computed tomography (CE-CT).
This is a prospective, randomized, phase 3, parallel-group, open-label, non-inferiority trial. Patients were randomly assigned 1:1 to receive prophylaxis against PC-AKI either with oral hydration: 500 mL of water two hours before and 2000 mL during the 24 h after performing CE-CT or i.v. hydration: sodium bicarbonate (166 mmol/L) 3 mL/kg/h starting one hour before and sodium bicarbonate (166 mmol/L) 1 mL/kg/h during the first hour after CE-CT. 100 mL of non-ionic iodinated contrast was administered in all cases. The primary outcome was the proportion of PC-AKI in the first 48-72 h after CE-CT. Secondary outcomes were persistent PC-AKI, the need for hemodialysis, and the occurrence of adverse events related to prophylaxis.
Of 264 patients randomized between January 2018 and January 2019, 114 received oral hydration, and 114 received i.v. hydration and were evaluable. No significant differences were found (p > 0.05) between arms in clinical characteristics or risk factors. PC-AKI rate was 4.4 % (95 %CI: 1.4-9.9 %) in the oral hydration arm and 5.3 % (95 %CI: 2.0-11.1%) in the i.v. hydration arm. The persistent PC-AKI rate was 1.8 % (95 %CI: 0.2-6.2 %) in both arms. No patient required dialysis during the first month after CE-CT or had adverse effects related to the hydration regime.
In those with stage IIIb CKD referred for an elective CE-CT, we provide evidence of non-inferiority of oral hydration compared to i.v. hydration in the prevention of PC-AKI.
评估口服补液与静脉补液(i.v.)在预防接受择期对比增强计算机断层扫描(CE-CT)的 IIIb 期慢性肾脏病(CKD)患者发生对比剂相关急性肾损伤(PC-AKI)中的非劣效性。
这是一项前瞻性、随机、III 期、平行组、开放标签、非劣效性试验。患者按 1:1 随机分配,分别接受 PC-AKI 预防治疗:口服补液组在进行 CE-CT 前 2 小时和 CE-CT 后 24 小时内分别口服 500ml 水和 2000ml 水;静脉补液组在进行 CE-CT 前 1 小时内开始静脉滴注 3ml/kg/h 的碳酸氢钠(166mmol/L),CE-CT 后 1 小时内静脉滴注 1ml/kg/h 的碳酸氢钠(166mmol/L)。所有患者均给予 100ml 非离子型碘对比剂。主要结局是 CE-CT 后 48-72 小时内 PC-AKI 的比例。次要结局是持续性 PC-AKI、需要血液透析以及与预防措施相关的不良事件的发生。
2018 年 1 月至 2019 年 1 月期间,264 例患者随机分组,其中 114 例接受口服补液,114 例接受静脉补液并可评估。两组在临床特征或危险因素方面无显著差异(p>0.05)。口服补液组 PC-AKI 发生率为 4.4%(95%CI:1.4-9.9%),静脉补液组为 5.3%(95%CI:2.0-11.1%)。两组持续性 PC-AKI 发生率均为 1.8%(95%CI:0.2-6.2%)。CE-CT 后第一个月内无患者需要透析或与补液方案相关的不良反应。
在接受择期 CE-CT 的 IIIb 期 CKD 患者中,我们提供了口服补液与静脉补液预防 PC-AKI 非劣效性的证据。